Literature DB >> 22987660

Adaptive prior variance calibration in the Bayesian continual reassessment method.

Jin Zhang1, Thomas M Braun, Jeremy M G Taylor.   

Abstract

The use of the continual reassessment method (CRM) and other model-based approaches to design Phase I clinical trials has increased owing to the ability of the CRM to identify the maximum tolerated dose better than the 3 + 3 method. However, the CRM can be sensitive to the variance selected for the prior distribution of the model parameter, especially when a small number of patients are enrolled. Although methods have emerged to adaptively select skeletons and to calibrate the prior variance only at the beginning of a trial, there has not been any approach developed to adaptively calibrate the prior variance throughout a trial. We propose three systematic approaches to adaptively calibrate the prior variance during a trial and compare them via simulation with methods proposed to calibrate the variance at the beginning of a trial.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22987660      PMCID: PMC3561509          DOI: 10.1002/sim.5621

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  A simple technique to evaluate model sensitivity in the continual reassessment method.

Authors:  Ying Kuen Cheung; Rick Chappell
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

2.  Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer.

Authors:  J O'Quigley
Journal:  Biometrics       Date:  1992-09       Impact factor: 2.571

3.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

4.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

5.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

6.  The continual reassessment method in cancer phase I clinical trials: a simulation study.

Authors:  S Chevret
Journal:  Stat Med       Date:  1993-06-30       Impact factor: 2.373

7.  Practical modifications of the continual reassessment method for phase I cancer clinical trials.

Authors:  D Faries
Journal:  J Biopharm Stat       Date:  1994-07       Impact factor: 1.051

8.  A comparison of two phase I trial designs.

Authors:  E L Korn; D Midthune; T T Chen; L V Rubinstein; M C Christian; R M Simon
Journal:  Stat Med       Date:  1994-09-30       Impact factor: 2.373

9.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

10.  An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.

Authors:  S Møller
Journal:  Stat Med       Date:  1995 May 15-30       Impact factor: 2.373

View more
  2 in total

1.  Flexible Phase I-II design for partially ordered regimens with application to therapeutic cancer vaccines.

Authors:  Nolan A Wages; Craig L Slingluff
Journal:  Stat Biosci       Date:  2019-06-04

2.  Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.

Authors:  Caroline Petit; Adeline Samson; Satoshi Morita; Moreno Ursino; Jérémie Guedj; Vincent Jullien; Emmanuelle Comets; Sarah Zohar
Journal:  Stat Methods Med Res       Date:  2016-10-05       Impact factor: 3.021

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.